Screener
Anika Therapeutics ANIK Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -3.4%+61.7pp | -9.8%+43.3pp | -9.9%+36.6pp | -40.2%+19.2pp | -65.1%-20.6pp | |
| Returns | ||||||
| Return on equity | -2.9%+31.0pp | -8%+23.8pp | -7.5%+23.3pp | -20.2%+23.1pp | -33.9%-3.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.2× | 0.6×+0.2× | 0.6×+0.1× | 0.4×-0.2× | 0.4×-0.2× | |
| Liquidity | ||||||
| Current ratio | 4.5×-1.7× | 4.5×-1.3× | 4.7×-0.2× | 5.3×0.0× | 6.2×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Valuation | ||||||
| Market capitalization | $278.9M+123% | $194.31M-8.8% | $138.59M-42.5% | $135.53M-62.9% | $161.05M-56.4% | |
| Price / sales | 2.3×+1.0× | 1.7×-0.3× | 1.2×-0.8× | 1.6×-0.6× | 1.7×-0.5× | |
| Price / book | 2×+1.2× | 1.5×0.0× | 1×-0.6× | 0.9×-1.1× | 1.1×-0.7× |
FAQ
- Where do Anika Therapeutics's ratios come from?
- Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
